Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JS122
- Development stage
- Preclinical
- Lead developer
- Junshi Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JS122 is a small-molecule, second-generation irreversible selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) under development for oncology indications. It was in-licensed by Junshi Biosciences from Wigen Biomedicine as part of a portfolio of small-molecule anti-tumor drugs, including JS120 (IDH1 inhibitor), JS121 (SHP2 inhibitor), and JS123 (ATR inhibitor). Its highest disclosed development status is preclinical, with neoplasms listed as the therapeutic area. The drug is designed to covalently and selectively inhibit FGFR2 signaling, a pathway implicated in cancers with FGFR2 alterations such as fusions or mutations.
- Other names
- JS-122JS122JS 122
02
Targets
Beyond the preview
Go deeper on JS122.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JS122.